Market Access News | pharmaphorum

News

COVID-19 vaccine supplies in spotlight as immunisation campa...

Supplies of COVID-19 vaccines are in the spotlight as countries across the world step up their immunisation campaigns against the pandemic.

News

Scotland backs Roche’s Rozlytrek for ROS1 lung cancer

The Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of lung cancer, almost seven months after NICE backed the drug in England.

News

NHS and Kite sign access deal for Kite's cancer cell therapy...

NHS patients in England will be among the first in the world to receive Gilead’s Tecartus cancer cell therapy for certain types of lymphoma, after the company’s specialist Kite unit struck

News

Talking vaccines: Industry’s role in protecting the Gavi generation

Fauci backs Biden's plan for 100 million COVID-19 shots

A promise by president-elect Joe Biden to carry out 100 million coronavirus vaccinations in his first 100 days in power is “absolutely doable”, according to the US leading infectious diseas

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J’s Darzalex Faspro is first US therapy for rare blood dis...

Johnson & Johnson’s Darzalex Faspro has become the first product approved by the FDA to treat light chain (AL) amyloidosis, a rare and often fatal blood cell disorder.

News

NICE recommends interim funding for GSK's Zejula in ovarian ...

Women with newly-diagnosed advanced ovarian cancer have a new treatment option in England after NICE recommend interim funding for GlaxoSmithKline’s Zejula (niraparib) in final guidance.

COVID-19 vaccine supplies in spotlight as immunisation campa...

Scotland backs Roche’s Rozlytrek for ROS1 lung cancer

NHS and Kite sign access deal for Kite's cancer cell therapy...

Fauci backs Biden's plan for 100 million COVID-19 shots

J&J’s Darzalex Faspro is first US therapy for rare blood dis...

NICE recommends interim funding for GSK's Zejula in ovarian ...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks